ONCT to $6.50Price at bottom channel
Stochastic Momentum Index (SMI) at oversold level
TTM Squeeze momentum is down
Price at Fibonacci number
In @$4.31
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−11.69 USD
−39.48 M USD
785.00 K USD
2.65 M
About Oncternal Therapeutics, Inc.
Sector
CEO
James B. Breitmeyer
Headquarters
San Diego
Website
Founded
1997
FIGI
BBG000BX50F2
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.
$ONCT Oncternal Therapeutics Inc Target PT 11 and higherNASDAQ:ONCT Oncternal Therapeutics Inc
Target PT 11 and higher
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanize
Hitting the bottom of trend line.$ONCT there is a clear trend line and it seems to have strong support in 6.2 zone. Play for 10-15 percent bounce from here.
Oncternal Therapeutic ONCT - Bullish betThis small-cap is a long-time leader in the oncology industry and has been highly rated by analysts in recent weeks.
Oncternal Therapeutics, Inc. (ONCT) Q4 2020 Earnings Call Transcript: www.fool.com
Interesting analysis: stocksregister.com
ONCT=free money playbeautiful play to swing trade if you enter on bottom trendline dip! has been rejected off top trendline resistance 4 times in previous months so be cautious when entering here! of course resistance will turn into support if 10 breaks so be on the lookout for a bigger breakout!
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ONCT is 1.14 USD — it has decreased by −6.20% in the past 24 hours. Watch Oncternal Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Oncternal Therapeutics, Inc. stocks are traded under the ticker ONCT.
ONCT stock has fallen by −19.87% compared to the previous week, the month change is a 7.08% rise, over the last year Oncternal Therapeutics, Inc. has showed a −81.57% decrease.
We've gathered analysts' opinions on Oncternal Therapeutics, Inc. future price: according to them, ONCT price has a max estimate of 39.00 USD and a min estimate of 2.00 USD. Watch ONCT chart and read a more detailed Oncternal Therapeutics, Inc. stock forecast: see what analysts think of Oncternal Therapeutics, Inc. and suggest that you do with its stocks.
ONCT reached its all-time high on Apr 25, 2007 with the price of 33,096.00 USD, and its all-time low was 1.05 USD and was reached on Oct 14, 2024. View more price dynamics on ONCT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ONCT stock is 26.21% volatile and has beta coefficient of −0.69. Track Oncternal Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Oncternal Therapeutics, Inc. there?
Today Oncternal Therapeutics, Inc. has the market capitalization of 3.58 M, it has decreased by −14.19% over the last week.
Yes, you can track Oncternal Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Oncternal Therapeutics, Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
ONCT net income for the last quarter is −8.46 M USD, while the quarter before that showed −8.56 M USD of net income which accounts for 1.11% change. Track more Oncternal Therapeutics, Inc. financial stats to get the full picture.
No, ONCT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 14, 2024, the company has 27.00 employees. See our rating of the largest employees — is Oncternal Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Oncternal Therapeutics, Inc. EBITDA is −35.96 M USD, and current EBITDA margin is −5.31 K%. See more stats in Oncternal Therapeutics, Inc. financial statements.
Like other stocks, ONCT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Oncternal Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Oncternal Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Oncternal Therapeutics, Inc. stock shows the sell signal. See more of Oncternal Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.